Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity
Discussion
Analyzing the largest international real-world data set of people with MS with suspected/confirmed COVID-19 confirms that the use of anti-CD20 medication (both ocrelizumab and rituximab), as well as male sex, older age, progressive MS, and higher disability are associated with more severe course of COVID-19. (Source: Neurology Neuroimmunology and Neuroinflammation)
Source: Neurology Neuroimmunology and Neuroinflammation - August 29, 2022 Category: Neurology Authors: Simpson-Yap, S., Pirmani, A., Kalincik, T., De Brouwer, E., Geys, L., Parciak, T., Helme, A., Rijke, N., Hillert, J. A., Moreau, Y., Edan, G., Sharmin, S., Spelman, T., McBurney, R., Schmidt, H., Bergmann, A. B., Braune, S., Stahmann, A., Middleton, R. M. Tags: COVID-19, Multiple sclerosis, All epidemiology, Risk factors in epidemiology Research Article Source Type: research
Anti ‐monoclonal antibody treatment during pregnancy and lactation in women with multiple sclerosis or neuromyelitis optica spectrum disorder
AbstractMultiple sclerosis (MS) and neuromyelitis optica (NMOSD) are more prevalent in women and mainly affecting young women, the majority of whom are of childbearing age. In addition, recent treatment algorithms suggest that patients who have poor prognostic factors are treated with highly effective disease-modifying drugs from the beginning. Anti-monoclonal antibodies for MS or NMOSD are basically highly effective disease-modifying drugs. Therefore, young women with MS or NMOSD will have more opportunities to receive anti-monoclonal antibody treatment than ever before. Currently, five anti-monoclonal antibodies for MS o...
Source: Clinical and Experimental Neuroimmunology - August 23, 2022 Category: Neurology Authors: Chiyoko Nohara Tags: INVITED REVIEW Source Type: research
116 Evaluating the introduction of subcutaneous natalizumab to a cohort of patients with multiple sclerosis
Conclusion
Subcutaneous natalizumab is a well-tolerated alternative to the intravenous infusion. In this cohort of patients, the majority were satisfied with switching, finding the SC injection more convenient, although some patients reported more pain especially when delivered in the arm. A major benefit to patients and staff is reduced delivery time, improving access to valuable infusion space. Monitoring will be reduced further to 15 minutes, once patients have received 6 injections. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - August 12, 2022 Category: Neurosurgery Authors: Edwards, M., Pearson, O., Ingram, G. Tags: Poster presentations Source Type: research
120 UK multiple sclerosis registries project: disease modifying treatment durability
Conclusion
This multi-centre study has revealed highly variable durability between DMTs over time, which may impact real-world effectiveness. These results may inform DMT clinical decision-making and improve outcomes for pwMS. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - August 12, 2022 Category: Neurosurgery Authors: Froud, J., John, F. S., Willis, M., Anderson, V., Uzochukwu, E., Thomas, R. W.-, Harding, K., Tallantyre, E., Robertson, N., et al Tags: Poster presentations Source Type: research
131 Understanding the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis
Conclusions
While active HCP time varies across sites, infusion DMTs are projected to require the greatest amount of HCP time associated with administration and monitoring over 4 years versus oral DMTs. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - August 12, 2022 Category: Neurosurgery Authors: Rog, D., Brownlee, W., Carod-Artal, F. J., Kalra, S., Cock, E. D., Leclerc, S., Amin, A., Ashton, L., Evans, H. Tags: Poster presentations Source Type: research
135 The UK MS pregnancy register: baseline data from the first fifty enrolled patients
Conclusions
These results show that a patient-facing pregnancy MS registry is feasible and can collect previous adverse pregnancy outcomes. Future results will inform clinicians and women about the safety of DMT and adjunctive medication during pregnancy and postpartum. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - August 12, 2022 Category: Neurosurgery Authors: Iyer, P., Craig, E., Brex, P., Ford, H., Hughes, S., Middleton, R., Murray, K., Pearson, O., Rog, D., Dobson, R. Tags: Poster presentations Source Type: research
136 NOVA primary results randomised controlled study of natalizumab Q6W versus continued Q4W treatment for MS
Conclusions
Overall, NOVA data suggest most patients stable on natalizumab Q4W can switch to Q6W without clinically meaningful loss of efficacy. Support: Biogen. Disclosures on poster. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - August 12, 2022 Category: Neurosurgery Authors: Foley, J., Defer, G., Ryerson, L. Z., Cohen, J., Arnold, D., Butzkueven, H., Cutter, G., Giovannoni, G., Killestein, J. Tags: Poster presentations Source Type: research
140 Long-term effectiveness of natalizumab for RRMS: UK and global interim results from TYSABRI observational program
Conclusions
The reduction in ARR on natalizumab was similar in the TOP UK and global cohorts, including in the subset of patients with one prior DMT. These findings support the real-world effectiveness of natalizumab.
Support
Biogen. Disclosures on poster. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - August 12, 2022 Category: Neurosurgery Authors: Nicholas, R., Harrower, T., Sun, Z., Vonsy, J. Tags: Poster presentations Source Type: research
152 AttackMS natalizumab for the treatment of people with inflammatory demyeli- nation suggestive of multiple sclerosis
Conclusions
AttackMS will be the first trial of HE-DMT in people with a first event of demyelination, in a hyper-acute setting. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - August 12, 2022 Category: Neurosurgery Authors: Schmierer, K., Redha, I., Hammond, V., Baker, D., Barkhof, F., Hooper, R., Rashid, W., Singh-Curry, V., Hobart, J., Giovannoni, G. Tags: Poster presentations Source Type: research
157 Natalizumab treatment satisfaction in the TONiC-MS study: study design
This study will provide real-world data on experience with natalizumab-i.v. and natalizumab-s.c. in the UK. The data collected will allow examination of quality of life, MS psychological impact, well-being and adverse events on the different formulations of natalizumab. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - August 12, 2022 Category: Neurosurgery Authors: James, B., Mills, R., Vonsy, J., Langdon, D., Ando, H., Young, C. Tags: Poster presentations Source Type: research
158 Natalizumab treatment satisfaction in TONiC-MS study: preliminary results from i.v.participants on infusion experience
Discussion
This is the first UK real-world study on natalizumab patients’ perceptions. These preliminary results highlight cannulation challenges experienced by some i.v. patients. As some patients switch to s.c., we will assess differences and patient preference between the two formulations. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - August 12, 2022 Category: Neurosurgery Authors: James, B., Mills, R., Vonsy, J., Langdon, D., Ando, H., Young, C. Tags: Poster presentations Source Type: research
Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS)
Conclusions
Routinely collected healthcare data can be used to evaluate DMT safety in people with MS. These data highlight the potential of pragmatic studies to guide understanding of risks and benefits associated with DMT. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - August 12, 2022 Category: Neurosurgery Authors: Dobson, R., Craner, M., Waddingham, E., Miller, A., Pindoria, J., Cavey, A., Matthews, P. M., on behalf of all OPTIMISE:MS investigators Tags: Parallel Session 5: MS and neuroinflammation Fri 20 May, 1130 - 1245 5 Source Type: research
SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod
Conclusions
The lack of immunogenicity under long-term fingolimod treatment demonstrates that functional immune responses require not only immune cells themselves, but also access of these cells to the site of inoculation and their unimpeded movement. The absence of humoral and T cell responses suggests that fingolimod-treated patients with MS are at risk for severe SARS-CoV-2 infections despite booster vaccinations, which is highly relevant for clinical decision-making and adapted protective measures, particularly considering additional recently approved sphingosine-1-phosphate receptor antagonists for MS treatment. (Sour...
Source: Journal of Neurology, Neurosurgery and Psychiatry - August 12, 2022 Category: Neurosurgery Authors: Meyer-Arndt, L., Braun, J., Fauchere, F., Vanshylla, K., Loyal, L., Henze, L., Kruse, B., Dingeldey, M., Jürchott, K., Mangold, M., Maraj, A., Braginets, A., Böttcher, C., Nitsche, A., de la Rosa, K., Ratswohl, C., Sawitzki, B., Holenya, P Tags: Open access, COVID-19 Multiple sclerosis Source Type: research
Treatment Options in Refractory Autoimmune Encephalitis
AbstractAutoimmune encephalitis represents a potentially treatable immune-mediated condition that is being more frequently recognized. Prompt immunotherapy is a key factor for the management of autoimmune encephalitis. First-line treatments include intravenous steroids, plasma exchange, and intravenous immunoglobulins, which can be combined in most severe cases. Rituximab and cyclophosphamide are administered as second-line agents in unresponsive cases. A minority of patients may still remain refractory, thus representing a major clinical challenge. In these cases, treatment strategies are controversial, and no guidelines ...
Source: CNS Drugs - August 2, 2022 Category: Neurology Source Type: research
Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010 –2019
ConclusionDMT cost is a key driver of the overall healthcare expenditure in MS. Future comparative and cost-effectiveness studies integrating claims and electronic health records data with better balancing of patient characteristics are warranted. (Source: Neurology and Therapy)
Source: Neurology and Therapy - July 30, 2022 Category: Neurology Source Type: research
